Pradigastat
drug drugOn this page
Also known as Lcq-908LCQ-908NXAC0088797
Summary
Pradigastat (CHEMBL2364624) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including metabolic dysfunction-associated steatotic liver disease and hepatitis c virus infection.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 6 conditions
- Clinical trials: 2
- Chemistry: 455.5 Da · C25H24F3N3O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2364624 |
| Name | Pradigastat |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 53387035 |
| Molecular formula | C25H24F3N3O2 |
| Molecular weight | 455.5 |
| InChIKey | GXALXAKNHIROPE-UHFFFAOYSA-N |
SMILES: C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)NC4=CN=C(C=C4)C(F)(F)F
IUPAC name: 2-[4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl]cyclohexyl]acetic acid
Also known as: Lcq-908, LCQ-908NXA, Pradigastat, PRADIGASTAT, pradigastat, C0088797
Parent form; salt/anhydrous children: CHEMBL2364625
Patent coverage: 102 distinct patent families (303 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 258 (85%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Diacylglycerol O-acyltransferase 1, Diacylglycerol O-acyltransferase 1.
Bioactivity
ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| DGAT1 | 7.26 | IC50 | 55 | nM | CHEMBL_ACT_18855078 |
| DGAT1 | 7.26 | IC50 | 55 | nM | CHEMBL_ACT_29118976 |
| DGAT1 | 7.18 | IC50 | 66 | nM | CHEMBL_ACT_24842818 |
| Q9Z2A7 | 7.15 | EC50 | 71 | nM | CHEMBL_ACT_18855088 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| metabolic dysfunction-associated steatotic liver disease | 2 | MONDO:0013209 | EFO:0003095 |
| hepatitis C virus infection | 2 | MONDO:0005231 | EFO:0003047 |
| constipation disorder | 2 | MONDO:0002203 | HP:0002019 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
| hyperlipoproteinemia | 1 | MONDO:0037748 | MONDO:0037748 |
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01474434 | PHASE2 | TERMINATED | Efficacy of LCQ908 on Cardiovascular Risk |
| NCT04620161 | PHASE2 | COMPLETED | A Proof of Concept Study of Pradigastat in Patients With Functional Constipation |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: metabolic dysfunction-associated steatotic liver disease, hepatitis C virus infection, constipation disorder